Compare GSK plc (GSK) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs JPMorgan Equity Premium Income ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while JPMorgan Equity Premium Income ETF trades at $56.77 (market cap $45.55B). The key difference: GSK plc is far larger — about 2× JPMorgan Equity Premium Income ETF's market cap, and GSK plc pays a 3.9% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and JPMorgan Equity Premium Income ETF for 57 Days on average.
| GSK | JEPI | |
|---|---|---|
Market Cap | $91.88B | $45.55B |
Volume | 7,730,529 | 3,820,809 |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $59.88 |
52-Week Low | $43.24 | $55.29 |
Typical Hold Time | 93 Days | 57 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
JEPI trades at $56.77, up 0.57% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF shows consistent dividend payments with recent distributions of $0.34-$0.37, positioning it as an income-focused vehicle. Recent news highlights JEPI's role in retirement income strategies and its appeal to investors seeking monthly distributions from covered call strategies.
The outlook remains cautious given the bearish technical setup, though the income generation capability provides downside cushion. Key risks include market volatility impacting the covered call strategy and interest rate sensitivity. Institutional interest continues with recent position increases, supporting the ETF's income-oriented appeal in uncertain markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
